Tuesday - July 8, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals
Chimerix

Ardent Health Announces First Quarter 2025 Results Conference Call and Webcast Date

April 22, 2025 | Last Trade: US$13.30 0.09 -0.67

BRENTWOOD, Tenn. / Apr 22, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first quarter 2025 results after the market closes on Tuesday, May 6, 2025. A conference call will be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent’s website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

United States Live:

 

1-888-596-4144

International Live:

 

1-646-968-2525

Access Code:

 

4437657

To listen to a replay of the teleconference, which will be available through May 21, 2025:

United States Replay:

 

1-800-770-2030

International Replay:

 

1-609-800-9909

Access Code:

 

4437657

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Assertio

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page